Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Suzetrigine (VX-548) in Painful Diabetic Peripheral Neuropathy
NCT05660538Phase 2Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Dec 2022
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of suzetrigine in diabetic peripheral neuropathy (DPN) (4 arms), sponsored by Vertex Pharmaceuticals. Primary endpoint: Numeric Pain Rating Scale at 12 weeks. Started Dec 2022; status: completed.
02
Drugs
suzetrigine
03
Conditions
diabetic peripheral neuropathy (DPN)
Beyond the preview
Go deeper on NCT05660538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05660538.